Phase I study of Erlotinib with Cisplatin, Pemetrexed, and Bevacizumab for chemotherapy naive advanced non-squamous non small cell lung cancer harboring EGFR mutatio
Phase 1
- Conditions
- advanced non squamous non small cell lung cancer
- Registration Number
- JPRN-UMIN000012536
- Lead Sponsor
- Osaka Prefectural Medical Center for Respiratory and Allergic diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)Serious infections 2)Serious clinical problems 3)Interstitial pneumonia/lung fibrosis on chest CT 4)Active concomitant malignancy 5)Symptomatic brain metastasis 6)Massive pericardial, pleural effusion, ascites 7)Previous drug allergy 8)not adequated for bevacizumab 9)Those judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To examine the dose limiting toxicity (DLT)To determine the maximum tolerated dose (MTD) and recomended dose (RD )
- Secondary Outcome Measures
Name Time Method efficacy, toxicity, PFS, OS